Research Focus
Genetic risk in Alzheimer's disease is particularly associated with alleles such as APOE ε4. Furthermore, genetic variants affecting beta-amyloid and tau protein metabolism contribute to disease progression. CYP450 enzyme variants (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4) in the metabolism of cholinesterase inhibitors may affect treatment outcomes.
The Alzheimer's Study Group, which operates within the Center for Personalized Treatment (KİMER), continues its work with an innovative vision aiming to analyze the genetic and pharmacogenetic basis of Alzheimer's disease. This group focuses on the following objectives with the aim of developing individualized treatment strategies:
Goals of the Working Group:
- Pharmacogenetic Perspective: To examine the role of genetic factors in the metabolism of drugs used in the treatment of Alzheimer's disease
- Genetic Predisposition: Identifying genetic variations that confer risk for Alzheimer's disease and building models that can predict risk.
- Clinical Applications: Develop genetics-based personalized treatment panels that can be used in the treatment of Alzheimer's disease.
These focus areas have the potential for individualized treatment of Alzheimer's disease at both the scientific and clinical level. By integrating genetic data into clinical practice, the working group aims to develop strategies that optimize each individual's response to treatment.